Skip to main content

FDA

Sharing New Research on Vaccinology

Leading global experts will share cutting-edge research on addressing vaccine hesitancy and new vaccines to prevent Zika, dengue, influenza, and antimicrobial resistance in Baltimore at the NFID 2019 Annual Conference on Vaccinology Research…

#GetVaccinated to Help #FightFlu and #PreventPneumo

US Surgeon General Jerome M. Adams, MD, MPH joined medical/public health leaders at the annual NFID Influenza/Pneumococcal News Conference on September 27, 2018 to discuss the importance of preventing influenza (flu) and pneumococcal disease and to encourage all individuals age 6 months and older to get vaccinated against flu every year. Adams was joined by an expert panel, moderated by…

Healthcare Professionals Play a Critical Role in Protecting Older Adults Against Influenza (Flu)

Did you know that in the US, adults age 65 years and older account for more than half (50-70%) of flu-related hospitalizations and most (85%) flu-related deaths?

The phenomenon known as immunosenescence describes how the body grows weaker with aging, making the immune system less effective in fighting off infections. As a result, adults age 65+ have an increased risk of hospitalization and complications from flu…

ID News Round-Up

Recent items of interest from the world of infectious diseases including the latest influenza vaccine recommendations, new policies from AAP to boost childhood immunization rates, new guidelines for the treatment of common sexually transmitted diseases, Zika in the US, and the FDA ban on some common antibacterial ingredients in soaps and body washes.

National Patient Safety Week: Focus on Antimicrobial Resistance

With a focus on increasing awareness of patient safety among healthcare professionals and consumers, National Patient Safety Awareness Week provides an opportunity to highlight an issue that affects more than 700,000 patients each year—healthcare-associated infections.

Working Towards a Universal Influenza Vaccine

A universal influenza vaccine would be an exciting new advancement and would revolutionize a vaccination strategy that has remained largely unchanged for over 50 years. An attractive future is on the rise in which an individual would need to receive only two vaccinations over his or her lifetime to protect against the many commonly circulating influenza virus strains, as well as possible emergent pandemic strains.

Focusing on Today’s Challenges to Deliver Tomorrow’s Vaccines

Advances in science and technology are giving rise to research and development for new vaccines. Additionally, innovative manufacturing approaches are being applied in the production of these products. This is especially true for vaccines necessary to address global patient population needs in developing countries and international markets.

Vaccine Safety: What You Should Know

The independent and multi-layered vaccine review process can be complicated but is in place to ensure that vaccines are held to the highest standards of safety. Moreover, continuous monitoring of health problems after vaccination ensures that the US has a safe and effective vaccine supply.

Meningitis B Vaccine: Part of the Routine Vaccine Schedule?

Adding a vaccine to the recommended schedule is not without controversy. All vaccines cost money—the meningococcal B vaccine costs around $130 a dose and currently the two vaccines available are part of a 2- or 3-dose series. However, the benefits of vaccination far out weigh the cost of vaccination.

Addressing the Challenges of Meningococcal Disease Outbreaks on Campuses

Recent outbreaks of serogroup B meningococcal disease on US college campuses have heightened awareness about the lack of licensed vaccines in the US to protect against this serious and sometimes fatal infection. The increased focus on the challenges of facing this unpredictable disease and the need for an effective and timely public health response when outbreaks occur, led the National Foundation for Infectious…